Press Release
-
- (2025-01-14) AimedBio Signs Exclusive Global Licensing Agreement with Biohaven for FGFR3 ADC, AMB302
- 2025.10.14
-
- (2024-12-10) AMB302, recognized as an Outstanding Project of 2024 by KDDF
- 2025.10.14
-
- (2024-11-22) The 2nd Samsung Medical Center X AimedBio ADC Conference
- 2025.10.14
-
- (2024-11-01) AimedBio’s FGFR3 ADC, AMB302, Cleared by the U.S. FDA to Begin Phase 1 Clinical Trial
- 2025.10.14
-
- (2024-07-21) AimedBio secures ₩40 billion (USD 28 million) Series B funding
- 2025.10.14
-
- (2024-04-08) AMB302’s poster presentation at AACR 2024
- 2025.10.14
-
- (2023-12-13) AMB302, selected as a KDDF project
- 2025.10.14
-
- (2023-09-13) Samsung Chooses AimedBio for its First Domestic Investment with 'Life Science Fund'
- 2023.09.14
-
- (2023-07-06) Third pipeline selected for the 'KDDF' grant focuses on allergy
- 2023.07.18
-
- (2023-06-30) 'The 1st Samsung Medical Center X AimedBio ADC Conference' ends in great success
- 2023.07.18
